Skip to main content

Table 5 Multivariate logistic regression analysis of established and experimental factors for predicting a pathological complete response, irrespective of study treatment: clinical response after two cycles excluded from second analysis

From: Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast

 

First analysis

Second analysis

 

Odds ratio

95% CI

p Value

Odds ratio

95% CI

p Value

Menopausal status

1.63

0.44 to 6.05

0.467

1.89

0.55 to 6.51

0.312

Tumour size

1.75

0.46 to 6.68

0.411

1.80

0.51 to 6.40

0.363

Clinical nodal status

5.48

1.24 to 24.16

0.025

5.44

1.35 to 21.87

0.017

Grade

0.21

0.03 to 1.33

0.098

0.16

0.03 to 0.91

0.039

Clinical response after two cycles

3.68

0.90 to 15.03

0.069

-

-

-

Hormonal receptor

27.00

2.21 to 330.57

0.010

7.83

1.24 to 49.42

0.029

Ki-67

0.75

0.16 to 3.56

0.716

0.78

0.18 to 3.39

0.740

HER2

4.09

0.70 to 24.08

0.119

3.66

0.69 to 19.30

0.126

p53

4.11

0.73 to 23.01

0.108

2.55

0.56 to 11.66

0.227

bcl-2

3.75

0.35 to 39.54

0.272

4.98

0.53 to 46.95

0.161

  1. HER2, human epidermal growth factor receptor 2.